Narcolepsy was first identified almost 130 years ago, but it was only 15 years ago that it was identified as a neurodegenerative disease linked to a loss of orexin neurons in the brain. It is unclear what causes the orexin neurons to die, but our strategy has been to place the gene for orexin into surrogate neurons in the validated mouse models of narcolepsy, and test whether it can block narcolepsy symptoms, such as cataplexy. In both the orexin knockout and the orexin-ataxin-3 mouse models of narcolepsy we have found that cataplexy can be blocked if the surrogate neurons are part of the circuit responsible for cataplexy. We have also determined that the orexin gene can be inserted into surrogate neurons in the amygdala to block emotion-induced cataplexy. Through the use of optogenetics we anticipate that it will be possible to preemptively block cataplexy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5511086PMC
http://dx.doi.org/10.1016/j.conb.2017.03.017DOI Listing

Publication Analysis

Top Keywords

models narcolepsy
12
surrogate neurons
12
block cataplexy
8
years ago
8
orexin neurons
8
mouse models
8
cataplexy
6
narcolepsy
5
orexin
5
neurons
5

Similar Publications

The Role and Mechanisms of the Hypocretin System in Zebrafish ().

Int J Mol Sci

December 2024

A.V. Zhirmunsky National Scientific Center of Marine Biology, Far Eastern Branch, Russian Academy of Sciences, 690041 Vladivostok, Russia.

Sleep is the most important physiological function of all animals studied to date. Sleep disorders include narcolepsy, which is characterized by excessive daytime sleepiness, disruption of night sleep, and muscle weakness-cataplexy. Narcolepsy is known to be caused by the degeneration of orexin-synthesizing neurons (hypocretin (HCRT) neurons or orexin neurons) in the hypothalamus.

View Article and Find Full Text PDF

Background: Stimulants are potent treatments for central hypersomnolence disorders or attention-deficit/hyperactivity disorders/attention deficit disorders but concerns have been raised about their potential negative consequences and their increasing prescription rates.

Objective: We aimed to describe stimulant prescription trends in Switzerland from 2014 to 2021. Second, we aimed to analyze the characteristics of individuals who received stimulant prescriptions in 2021 and investigate the link between stimulant prescriptions and hospitalization rates in 2021, using hospitalization as a potential indicator of adverse health outcomes.

View Article and Find Full Text PDF

LPSGM: A Unified Flexible Large PSG Model for Sleep Staging and Mental Disorder Diagnosis.

medRxiv

December 2024

Affiliated Mental Health Center & Hangzhou Seventh People's Hospital, School of Brain Science and Brain Medicine, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310058, China.

We present the Large PSG Model (LPSGM), a unified and flexible framework for sleep staging and disease diagnosis using polysomnography (PSG) data. LPSGM is designed to address the challenges of cross-center generalization in sleep staging and to enable fine-tuning for downstream disease diagnosis tasks. LPSGM introduces a unified training framework for heterogeneous datasets and allows flexible channel input adjustments during inference.

View Article and Find Full Text PDF

Background: Patient experience data from social media offer patient-centered perspectives on disease, treatments, and health service delivery. Current guidelines typically rely on systematic reviews, while qualitative health studies are often seen as anecdotal and nongeneralizable. This study explores combining personal health experiences from multiple sources to create generalizable evidence.

View Article and Find Full Text PDF

The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review.

Int J Mol Sci

November 2024

Department of Immunology, College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang 471003, China.

Article Synopsis
  • - Narcolepsy type 1 (NT1) is a rare sleep disorder characterized by excessive daytime sleepiness, cataplexy, and disruptions in REM sleep, linked to the loss of neurons that produce a wakefulness-promoting neuropeptide called orexin.
  • - The condition's onset may be influenced by factors like genetic predisposition, environmental triggers, and especially an autoimmune reaction, with a noted increase in cases following certain viral infections and vaccinations.
  • - Research highlights the role of specific T cells in attacking orexin-producing neurons, emphasizing the need for further understanding of NT1's autoimmune mechanisms to develop effective treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!